Related posts
Markets rally to strongest week this yearYields and TSX climb, Wall Street flatEarnings optimism lifts marketsA good mix of consumer goods and healthcare, but the PE is extended. Prefers to buy Pfizer for its growth and lower PE. He might even roll the dice with Moderna. Or buy the IBB, biotech ETF.
Down 26% in the last 23 months. It's suffering a post-Covid hangover and the company is better than this.
Is down 22% in the last 3 months. But he would but it. They're out of fashion, sure, and it's considered a Covid name, but their science is very good. A personalized cancer vaccine is possible.
They have developed a vaccine template that will benefit them going forward. Do not sell, but add more.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
They're holding an investor event on Monday. They delivered an early Covid vaccine, but shares have fallen since then. A smart CEO. They're working on a personalized cancer medication.
Hold it and put it away. It is event-driven. Their cancer vaccine data is coming, for instance, and will do well. This is a long-term buy.
Likes it long term. They will reveal data on a personalized cancer vaccine coming up. But short term it's volatile, anybody's guess.
Moderna is a American stock, trading under the symbol MRNA-Q on the NASDAQ (MRNA). It is usually referred to as NASDAQ:MRNA or MRNA-Q
In the last year, 9 stock analysts published opinions about MRNA-Q. 8 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Moderna.
Moderna was recommended as a Top Pick by on . Read the latest stock experts ratings for Moderna.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
9 stock analysts on Stockchase covered Moderna In the last year. It is a trending stock that is worth watching.
On 2023-12-01, Moderna (MRNA-Q) stock closed at a price of $76.24.
Covid vaccine was its first commercial product, and it did well. That's trailing off. Investing in drug pipeline, and it's hard to determine when products might be approved and launched. Her preference is a more established company with a pipeline.